vTv Therapeutics Inc. (NASDAQ:VTVT) Sees Large Growth in Short Interest

vTv Therapeutics Inc. (NASDAQ:VTVT) was the recipient of a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 22,500 shares, an increase of 33.1% from the December 31st total of 16,900 shares. Approximately 1.5% of the shares of the company are sold short. Based on an average daily volume of 29,400 shares, the days-to-cover ratio is presently 0.8 days.

Institutional Trading of vTv Therapeutics

A hedge fund recently bought a new stake in vTv Therapeutics stock. FMR LLC acquired a new position in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 178,200 shares of the biotechnology company’s stock, valued at approximately $2,402,000. FMR LLC owned approximately 5.92% of vTv Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Stock Up 6.5 %

Shares of VTVT traded up $0.96 during mid-day trading on Friday, hitting $15.62. 13,070 shares of the company’s stock were exchanged, compared to its average volume of 7,390. vTv Therapeutics has a 52 week low of $8.03 and a 52 week high of $30.99. The stock’s 50-day simple moving average is $14.76 and its 200-day simple moving average is $15.13. The firm has a market cap of $49.83 million, a price-to-earnings ratio of -3.45 and a beta of 0.69.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.88) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, Alliance Global Partners assumed coverage on shares of vTv Therapeutics in a research note on Monday, December 9th. They issued a “buy” rating and a $35.00 price target on the stock.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.